NCT00402987

Testing The Effectiveness Of Celecoxib In Patients With Painful Sore Throat

A DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED COMPARISON OF THE EFFICACY, SAFETY, AND TOLERABILITY OF CELECOXIB 100-150 MG, INCLUDING INITIAL DOSES OF 50 AND 100 MG, AND PLACEBO IN THE SYMPTOMATIC TREATMENT OF PATIENTS WITH PAINFUL PHARYNGITIS

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 269 (actual)
• Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
• Sex: All
• Age: 18 Years – 18 Years
• Healthy volunteers: Not accepted

Summary

We are proposing a study in which we utilize and augment the sore throat pain model to assess the analgesic effectiveness of celecoxib compared to placebo in patients with painful pharyngitis under randomized, double-blind, placebo-controlled conditions.

Conditions

• Pharyngitis

Interventions

Type	Name	Description
DRUG	Celecoxib	dose 1 celecoxib 50 mg followed 6-12 hours later by dose 2 celecoxib 50 mg
DRUG	Celecoxib	dose 1 celecoxib 100 mg followed 6-12 hours later by dose 2 placebo
DRUG	celecoxib	dose 1 celecoxib 100 mg followed 6-12 hours later by dose 2 celecoxib 50 mg
DRUG	placebo	dose 1 placebo followed 6-12 hours later by dose 2 placebo

Timeline

• Start date: 2006-12-04
• Primary completion: 2007-11-15
• Completion: 2007-11-15
• First posted: 2006-11-23
• Last updated: 2021-03-03
• Results posted: 2009-03-12

Locations

1 site across 1 country: United States